IN2014CN03072A - - Google Patents

Info

Publication number
IN2014CN03072A
IN2014CN03072A IN3072CHN2014A IN2014CN03072A IN 2014CN03072 A IN2014CN03072 A IN 2014CN03072A IN 3072CHN2014 A IN3072CHN2014 A IN 3072CHN2014A IN 2014CN03072 A IN2014CN03072 A IN 2014CN03072A
Authority
IN
India
Prior art keywords
compositions
directed
production
methods
present
Prior art date
Application number
Other languages
English (en)
Inventor
Terrance A Stadheim
Daniel Cua
Dongxing Zha
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of IN2014CN03072A publication Critical patent/IN2014CN03072A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
IN3072CHN2014 2011-10-31 2012-10-26 IN2014CN03072A (en0)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161553335P 2011-10-31 2011-10-31
PCT/US2012/062211 WO2013066761A1 (en) 2011-10-31 2012-10-26 Method for preparing antibodies having improved properties

Publications (1)

Publication Number Publication Date
IN2014CN03072A true IN2014CN03072A (en0) 2015-07-31

Family

ID=48192651

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3072CHN2014 IN2014CN03072A (en0) 2011-10-31 2012-10-26

Country Status (9)

Country Link
US (1) US20140286946A1 (en0)
EP (1) EP2773661A4 (en0)
JP (1) JP2014532661A (en0)
KR (1) KR20140097245A (en0)
CN (1) CN104011076A (en0)
AU (1) AU2012332840A1 (en0)
CA (1) CA2853809A1 (en0)
IN (1) IN2014CN03072A (en0)
WO (1) WO2013066761A1 (en0)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
ES2739280T3 (es) 2013-07-04 2020-01-30 Glykos Finland Oy Células fúngicas filamentosas deficientes en O-manosiltransferasa y métodos de uso de las mismas
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CN106661099A (zh) 2014-05-27 2017-05-10 中央研究院 抗her2醣抗体及其用途
EP3904388A1 (en) * 2014-05-27 2021-11-03 Academia Sinica Fucosidase from bacteroides and methods using the same
TWI670078B (zh) 2014-05-27 2019-09-01 中央研究院 抗ｃｄ２０醣抗體及其用途
TWI732738B (zh) 2014-05-28 2021-07-11 中央研究院 抗TNF-α醣抗體及其用途
CN108064266A (zh) 2014-07-21 2018-05-22 格利科斯芬兰公司 在丝状真菌中具有哺乳动物样n-聚糖的糖蛋白的制备
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
RU2018123481A (ru) 2015-12-16 2020-01-20 Мерк Шарп И Доум Корп. Анти-lag3 антитела и антигенсвязывающие фрагменты
AU2017316663B2 (en) 2016-08-22 2024-02-22 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
CN114075269A (zh) * 2017-07-06 2022-02-22 菲仕兰坎皮纳荷兰私人有限公司 用于制备糖蛋白的细胞培养工艺

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20100173323A1 (en) * 2006-06-09 2010-07-08 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
FR2912154B1 (fr) * 2007-02-02 2012-11-02 Glycode Levures genetiquement modifiees pour la production de glycoproteines homogenes
JP5956982B2 (ja) * 2010-05-27 2016-07-27 メルク・シャープ・エンド・ドーム・コーポレイション 改善された特性を有する抗体の製造方法

Also Published As

Publication number Publication date
US20140286946A1 (en) 2014-09-25
EP2773661A4 (en) 2015-06-17
KR20140097245A (ko) 2014-08-06
WO2013066761A1 (en) 2013-05-10
AU2012332840A1 (en) 2014-05-15
JP2014532661A (ja) 2014-12-08
CN104011076A (zh) 2014-08-27
EP2773661A1 (en) 2014-09-10
CA2853809A1 (en) 2013-05-10

Similar Documents

Publication Publication Date Title
IN2014CN03072A (en0)
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
JOP20180103A1 (ar) مركب صيدلاني
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
MX2018010572A (es) Inmunoglobulinas heterodimericas.
IN2013MN00501A (en0)
MX2022000026A (es) Anticuerpos para tau.
IN2015DN00127A (en0)
IN2015DN03029A (en0)
MY177031A (en) Tetrahydropyridopyrazines modulators of gpr6
MX337549B (es) Derivados de insulina que contienen enlaces disulfuro adicionales.
IN2015DN00372A (en0)
MX348325B (es) Composicion que contiene galacto-oligosacarido y un metodo para producirla.
IN2014DN09450A (en0)
MX2011012623A (es) Construcciones de casb7439.
IN2014DN00254A (en0)
MX347541B (es) Analogos de acido sialico.
IN2013MU01113A (en0)
PH12016501201A1 (en) Synthesis of ent-progesterone and intermediates thereof
WO2013181599A3 (en) Methods related to rituximab
MX2013014420A (es) Composiciones en gel.
IN2013MU01290A (en0)
MX2014002378A (es) Proceso para la preparacion de (r)-2-acetamido-n-bencil-3-metoxipr opionamida e intermediarios de la misma.
MX2015012902A (es) Sintesis de ent-progesterona e intermediarios de la misma.
MX371011B (es) Intermediarios y métodos para sintetizar derivados de calicheamicina.